

**Die moderne Strahlentherapie als Therapieoption
bei nicht-melanozytären Hauttumoren (S. 8–13)**

M. Hudelist-Venz und C. Waldstein

Literatur:

1. Veness MJ et al. Current Role of Radiotherapy in Non-melanoma Skin Cancer. Clin Oncol (R Coll Radiol) 2019; 31(11): 749–58
 2. Benkhaled S et al. The State of the Art of Radiotherapy for Non-melanoma Skin Cancer: A Review of the Literature. Front Med (Lausanne) 2022; 9: 913269
 3. Rong Y et al. Radiotherapy treatment for nonmelanoma skin cancer. Expert Rev Anticancer Ther 2015; 15(7): 765–76
 4. Strom TJ et al. Harrison, Management of BCC and SCC of the Head and Neck. Cancer Control 2016; 23(3): 220–7
 5. Caparrotti F et al. Localized Non-melanoma Skin Cancer: Risk Factors of Post-surgical Relapse and Role of Postoperative Radiotherapy. Curr Treat Options Oncol 2020; 21(12): 97
 6. Likhacheva A et al. Definitive and Postoperative Radiation Therapy for Basal and Squamous Cell Cancers of the Skin: Executive Summary of an American Society for Radiation Oncology Clinical Practice Guideline. Pract Radiat Oncol 2020; 10(1): 8–20
 7. Thompson AK et al. Risk Factors for Cutaneous Squamous Cell Carcinoma Recurrence, Metastasis, and Disease-Specific Death: A Systematic Review and Meta-analysis. JAMA Dermatol 2016; 152(4): 419–28
 8. Manyam BV et al. A multi-institutional comparison of outcomes of immunosuppressed and immunocompetent patients treated with surgery and radiation therapy for cutaneous squamous cell carcinoma of the head and neck. Cancer 2017; 123(11): 2054–60
 9. Barnes EA et al. Palliative radiotherapy for non-melanoma skin cancer. Clin Oncol (R Coll Radiol) 2010; 22(10): 844–9
 10. De Felice F et al. Definitive weekly hypofractionated radiotherapy in cutaneous squamous cell carcinoma: response rates and outcomes in elderly patients unfit for surgery. Int J Dermatol 2022; 61(8): 911–15
 11. Marriappan L et al. Weekly radiotherapy for basal cell carcinoma in the frail and elderly. Br J Dermatol 2014; 171(5): 1237–9
 12. Moran JM & Phelps PO. Periocular skin cancer: Diagnosis and management. Dis Mon 2020; 66(10): 101046
-

Update: Immunologische Therapiekonzepte beim Multiplen Myelom (s. 24–29)

E. Bräunlein, A. M. Krackhardt

Literatur:

1. Jeryczynski G et al. Stratification for RRMM and Risk-Adapted Therapy: Sequencing of Therapies in RRMM. *Cancers (Basel)* 2021; 13(23)
2. Romano A et al. Mechanisms of Action of the New Antibodies in Use in Multiple Myeloma. *Front Oncol* 2021; 11: 684561
3. Tzogani K et al. EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma. *Oncologist* 2021; 26(1): 70–6
4. Collins S et al. 357 TAK-573, an anti-CD38–attenuated interferon alpha (IFN α) fusion protein (Attenukine™), has demonstrated IFN α receptor (IFNAR) pathway modulation in patients with relapsed/refractory multiple myeloma. *Journal for ImmunoTherapy of Cancer* 2020; 8(Suppl 3): A218
5. Smith EL et al. GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells. *Sci Transl Med* 2019; 11(485)
6. Elkins K et al. FcRL5 as a target of antibody-drug conjugates for the treatment of multiple myeloma. *Mol Cancer Ther* 2012; 11(10): 2222–32
7. Sherbenou DW et al. Potent Activity of an Anti-ICAM1 Antibody-Drug Conjugate against Multiple Myeloma. *Clin Cancer Res* 2020; 26(22): 6028–38
8. Sun C et al. Safety and efficacy of targeting CD138 with a chimeric antigen receptor for the treatment of multiple myeloma. *Oncotarget* 2019; 10(24): 2369–83
9. Fuchsl F & AM Krackhardt. Adoptive Cellular Therapy for Multiple Myeloma Using CAR- and TCR-Transgenic T Cells: Response and Resistance. *Cells* 2022; 11(3)
10. Cohen AD et al. Efficacy and safety of cilta-cel in patients with progressive MM after exposure to other BCMA-targeting agents. *Blood* 2022; blood.2022015526
11. Martin T et al. Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up. *J Clin Oncol* 2022; JCO2200842
12. Moreau P et al. Teclistamab in Relapsed or Refractory Multiple Myeloma. *N Engl J Med* 2022; 387(6): 495–505
13. Mailankody S & Landgren O. T-Cell Engagers - Modern Immune-Based Therapies for Multiple Myeloma. *N Engl J Med* 2022; 387(6): 558–61
14. (GSK), G. GSK provides an update on Blenrep (belantamab mafodotin-blmf) US marketing authorisation. 2022. (<https://www.gsk.com/en-gb/media/press-releases/gsk-provides-update-on-dreamm-3-phase-iii-trial-for-blenrep/>). Zugegriffen am 05.12.2022
15. Mailankody S et al. GPRC5D-Targeted CAR T Cells for Myeloma. *N Engl J Med* 2022; 387(13): 1196–206
16. Verkleij CPM et al. Preclinical activity and determinants of response of the GPRC5D \times CD3 bispecific antibody talquetamab in multiple myeloma. *Blood Adv* 2021; 5(8): 2196–215
17. Girgis S et al. Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed/refractory multiple myeloma. *Blood Adv* 2022; bloodadvances.2022007625

18. Rodríguez-Otero P et al. A novel, immunotherapy-based approach for the treatment of relapsed/refractory multiple myeloma (RRMM): Updated phase 1b results for daratumumab in combination with teclistamab (a BCMA x CD3 bispecific antibody). *J Clin Oncol* 2022; 40(16_suppl): 8032–8032
19. Kaufman JL et al. S181: MODAKAFUSP ALFA (TAK-573): UPDATED CLINICAL, PHARMACOKINETIC (PK), AND IMMUNOGENICITY RESULTS FROM A PHASE 1/2 STUDY IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM). *HemaSphere* 2022; 6
20. Stewart AK et al. Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma. *Blood Cancer J* 2019; 9(2): 17
21. Trudel S et al. Cevostamab Monotherapy Continues to Show Clinically Meaningful Activity and Manageable Safety in Patients with Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study. *Blood* 2021; 138: 157
22. Gogishvili T et al. SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7(+) normal lymphocytes. *Blood* 2017; 130(26): 2838–47
23. Prommersberger S et al. CARAMBA: a first-in-human clinical trial with SLAMF7 CAR-T cells prepared by virus-free Sleeping Beauty gene transfer to treat multiple myeloma. *Gene Ther* 2021; 28(9): 560–71
24. Boussi LS et al. Immunotherapy for the treatment of multiple myeloma. *Front Immunol* 2022; 13: 1027385
25. Lulla PD et al. The safety and clinical effects of administering a multiantigen-targeted T cell therapy to patients with multiple myeloma. *Sci Transl Med* 2020; 12(554)
26. Stadtmauer EA et al. Long-term safety and activity of NY-ESO-1 SPEAR T cells after autologous stem cell transplant for myeloma. *Blood Adv* 2019; 3(13): 2022–34
27. Rejeski K et al. CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma. *Blood* 2021; 138(24): 2499–2513
28. Rejeski K et al. The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL. *J Immunother Cancer* 2022; 10(5)
29. Gagelmann N et al. Access to and affordability of CAR T-cell therapy in multiple myeloma: an EBMT position paper. *Lancet Haematol* 2022; 9(10): e786–e795
30. Kegyes D et al. Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient? *J Hematol Oncol* 2022; 15(1): 78
31. Perrot A. How I treat frontline transplantation-eligible multiple myeloma. *Blood* 2022; 139(19): 2882–88
32. Gulla A et al. Bortezomib induces anti-multiple myeloma immune response mediated by cGAS/STING pathway activation. *Blood Cancer Discov* 2021; 2(5): 468–83
33. Cohen AD et al. Serial treatment of relapsed/refractory multiple myeloma with different BCMA-targeting therapies. *Blood Adv* 2019; 3(16): 2487–90
34. Gazeau N et al. Effective anti-BCMA retreatment in multiple myeloma. *Blood Adv* 2021; 5(15): 3016–20
35. Mikhael J et al. A phase 2 study of isatuximab monotherapy in patients with multiple myeloma who are refractory to daratumumab. *Blood Cancer J* 2021; 11(5): 89
36. Manier S et al. Current state and next-generation CAR-T cells in multiple myeloma. *Blood Rev* 2022; 54: 100929

37. Usmani SZ et al. Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial. *Lancet Haematol* 2019; 6(9): e448–58
38. Frerichs KA et al. Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients. *Cancers (Basel)* 2021; 13(10)
39. Goldstein RL et al. AMG 701 induces cytotoxicity of multiple myeloma cells and depletes plasma cells in cynomolgus monkeys. *Blood Adv* 2020; 4(17): 4180–94
40. Munshi NC et al. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. *N Engl J Med* 2021; 384(8): 705–16
41. Lonial S et al. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study. *Lancet Oncol* 2020; 21(2): 207–21
42. Minnema MC et al. Efficacy and safety of talquetamab, a G protein-coupled receptor family C group 5 member D x CD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM): Updated results from MonumentAL-1. *Journal of Clinical Oncology* 2022; 40(16_suppl): 8015–8015
43. Kelly KR et al. Indatuximab ravtansine plus dexamethasone with lenalidomide or pomalidomide in relapsed or refractory multiple myeloma: a multicentre, phase 1/2a study. *Lancet Haematol* 2021; 8(11): e794–807